Reported Earnings • May 31
Full year 2026 earnings released: EPS: ₹0.73 (vs ₹12.23 loss in FY 2025) Full year 2026 results: EPS: ₹0.73 (up from ₹12.23 loss in FY 2025). Revenue: ₹7.64b (down 3.1% from FY 2025). Net income: ₹17.2m (up ₹305.2m from FY 2025). Profit margin: 0.2% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Reported Earnings • Feb 14
Third quarter 2026 earnings released: ₹2.53 loss per share (vs ₹3.05 loss in 3Q 2025) Third quarter 2026 results: ₹2.53 loss per share (improved from ₹3.05 loss in 3Q 2025). Revenue: ₹1.86b (down 5.9% from 3Q 2025). Net loss: ₹59.5m (loss narrowed 17% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Nov 16
Second quarter 2026 earnings released: ₹5.25 loss per share (vs ₹6.81 loss in 2Q 2025) Second quarter 2026 results: ₹5.25 loss per share (improved from ₹6.81 loss in 2Q 2025). Revenue: ₹1.83b (down 9.5% from 2Q 2025). Net loss: ₹123.6m (loss narrowed 23% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. New Risk • Oct 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹2.55b market cap, or US$29.0m). New Risk • Sep 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (₹2.21b market cap, or US$25.0m). Announcement • Aug 18
Bilcare Limited, Annual General Meeting, Sep 24, 2025 Bilcare Limited, Annual General Meeting, Sep 24, 2025. Reported Earnings • Aug 16
First quarter 2026 earnings released: ₹1.59 loss per share (vs ₹2.71 loss in 1Q 2025) First quarter 2026 results: ₹1.59 loss per share (improved from ₹2.71 loss in 1Q 2025). Revenue: ₹1.92b (flat on 1Q 2025). Net loss: ₹37.3m (loss narrowed 42% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Aug 09
Bilcare Limited to Report Q1, 2026 Results on Aug 14, 2025 Bilcare Limited announced that they will report Q1, 2026 results on Aug 14, 2025 New Risk • May 30
New major risk - Revenue and earnings growth Earnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹1.85b market cap, or US$21.6m). Reported Earnings • May 30
Full year 2025 earnings released: ₹12.22 loss per share (vs ₹14.12 loss in FY 2024) Full year 2025 results: ₹12.22 loss per share (improved from ₹14.12 loss in FY 2024). Revenue: ₹8.07b (up 7.9% from FY 2024). Net loss: ₹287.8m (loss narrowed 13% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Feb 15
Third quarter 2025 earnings released: ₹3.05 loss per share (vs ₹2.91 loss in 3Q 2024) Third quarter 2025 results: ₹3.05 loss per share (further deteriorated from ₹2.91 loss in 3Q 2024). Revenue: ₹1.98b (up 13% from 3Q 2024). Net loss: ₹71.7m (loss widened 4.7% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Announcement • Jan 10
Bilcare Limited Announces Resignation of Dr. Abhigyan Upadhyay as an Executive Director Bilcare Limited at the board meeting held on Janaury 10, 2025 noted Resignation of Dr. Abhigyan Upadhyay as an Executive Director with effect from January 9, 2025. Dr. Abhigyan Upadhyay, vide his letter dated January 9, 2025 has tendered his resignation as an Non-Executive, Non-Independent Director of the Company with immediate effect. Mr. Abhigyan Upadhyay in his letter dated 9 January, 2025 has also confirmed that there are no other material reasons for his resignation other than those mentioned in the resignation letter. Reasons: personal reasons. New Risk • Dec 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹1.66b market cap, or US$19.5m). Reported Earnings • Nov 15
Second quarter 2025 earnings released: ₹6.81 loss per share (vs ₹3.22 loss in 2Q 2024) Second quarter 2025 results: ₹6.81 loss per share (further deteriorated from ₹3.22 loss in 2Q 2024). Revenue: ₹2.06b (up 8.3% from 2Q 2024). Net loss: ₹160.3m (loss widened 111% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Board Change • Sep 15
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Alka Sagar was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Sep 11
Bilcare Limited, Annual General Meeting, Sep 27, 2024 Bilcare Limited, Annual General Meeting, Sep 27, 2024, at 12:30 Indian Standard Time. Reported Earnings • Aug 16
First quarter 2025 earnings released: ₹2.71 loss per share (vs ₹3.36 loss in 1Q 2024) First quarter 2025 results: ₹2.71 loss per share (improved from ₹3.36 loss in 1Q 2024). Revenue: ₹1.98b (up 8.6% from 1Q 2024). Net loss: ₹63.9m (loss narrowed 19% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 8% per year. Announcement • Aug 08
Bilcare Limited to Report Q1, 2025 Results on Aug 14, 2024 Bilcare Limited announced that they will report Q1, 2025 results on Aug 14, 2024 Reported Earnings • May 28
Full year 2024 earnings released: ₹14.11 loss per share (vs ₹6.39 profit in FY 2023) Full year 2024 results: ₹14.11 loss per share (down from ₹6.39 profit in FY 2023). Revenue: ₹7.70b (down 22% from FY 2023). Net loss: ₹332.3m (down 321% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • May 09
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Pramod Toshniwal was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹64.85, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 28x in the Life Sciences industry in India. Total returns to shareholders of 18% over the past three years. Announcement • Mar 28
Bilcare Limited Announces Resignation of Prabhavi Mungee as Company Secretary & Compliance Officer Bilcare Limited announced the resignation of Ms. Prabhavi Mungee as company secretary & compliance officer of the company with effect from 10 November 2023. Board Change • Mar 14
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Non-Executive Independent Director Rajesh Devene is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹57.22, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 7.6% over the past three years. Reported Earnings • Feb 14
Third quarter 2024 earnings released: ₹2.91 loss per share (vs ₹7.98 loss in 3Q 2023) Third quarter 2024 results: ₹2.91 loss per share (improved from ₹7.98 loss in 3Q 2023). Revenue: ₹1.79b (down 27% from 3Q 2023). Net loss: ₹68.5m (loss narrowed 64% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 9% per year. Announcement • Oct 06
Bilcare Limited Announces Resignation of Ashwani Singh as an Independent Director Bilcare Limited informed the exchange that Mr. Ashwani Singh (DIN 08855493), vide his letter dated 4th October, 2023 has tendered his resignation as an Independent Director of the Company with immediate effect. The Board of Directors of the Company noted his communication. Announcement • Sep 07
Bilcare Limited Appoints Deepa Mathur as the Chief Financial Officer Bilcare Limited announces appointment of Ms. Deepa Mathur as the Chief Financial Officer with effect from 6th September, 2023. Deepa Mathur, a professional with more than twenty five years of experience in the corporate world having skill sets in varied aspects of finance, banking, compliance, taxation legal, structuring of transactions and other allied activities. Is a CA with an expertise of turnaround of business crisis both financial and strategic. Announcement • Sep 02
Bilcare Limited Announces Resignation of Nilesh Tiwari as Chief Financial Officer Bilcare Limited announced that Mr. Nilesh Tiwari, chief financial officer and key managerial personnel of the company has tendered his resignation vide letter dated 31 August 2023, due to personal reasons and he has been relieved from his duties effective end of business hours of 31 August 2023. Reported Earnings • Aug 16
First quarter 2024 earnings released: ₹3.36 loss per share (vs ₹2.84 loss in 1Q 2023) First quarter 2024 results: ₹3.36 loss per share (further deteriorated from ₹2.84 loss in 1Q 2023). Revenue: ₹1.86b (down 25% from 1Q 2023). Net loss: ₹79.1m (loss widened 18% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹87.86, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 81% over the past three years. Announcement • Aug 08
Bilcare Limited to Report Q1, 2024 Results on Aug 14, 2023 Bilcare Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Aug 14, 2023 Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹63.35, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 31x in the Life Sciences industry in India. Total returns to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₹55.92, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 72% over the past three years. Reported Earnings • Jun 02
Full year 2023 earnings released: EPS: ₹6.39 (vs ₹5.35 loss in FY 2022) Full year 2023 results: EPS: ₹6.39 (up from ₹5.35 loss in FY 2022). Revenue: ₹9.92b (up 17% from FY 2022). Net income: ₹150.5m (up ₹276.4m from FY 2022). Profit margin: 1.5% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 10
Third quarter 2023 earnings released: ₹7.98 loss per share (vs ₹5.90 loss in 3Q 2022) Third quarter 2023 results: ₹7.98 loss per share (further deteriorated from ₹5.90 loss in 3Q 2022). Revenue: ₹2.52b (up 21% from 3Q 2022). Net loss: ₹187.7m (loss widened 35% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 55% per year whereas the company’s share price has increased by 54% per year. Buying Opportunity • Jan 25
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be ₹67.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 47% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Nov 19
Second quarter 2023 earnings released: ₹2.42 loss per share (vs ₹9.51 profit in 2Q 2022) Second quarter 2023 results: ₹2.42 loss per share (down from ₹9.51 profit in 2Q 2022). Revenue: ₹2.57b (up 26% from 2Q 2022). Net loss: ₹56.9m (down 125% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 11
First quarter 2023 earnings released: ₹2.84 loss per share (vs ₹6.49 loss in 1Q 2022) First quarter 2023 results: ₹2.84 loss per share (up from ₹6.49 loss in 1Q 2022). Revenue: ₹2.51b (up 41% from 1Q 2022). Net loss: ₹66.9m (loss narrowed 56% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 13
Full year 2022 earnings released: ₹5.35 loss per share (vs ₹8.95 loss in FY 2021) Full year 2022 results: ₹5.35 loss per share (up from ₹8.95 loss in FY 2021). Revenue: ₹8.45b (up 36% from FY 2021). Net loss: ₹125.9m (loss narrowed 40% from FY 2021). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 25
Full year 2022 earnings released: ₹5.35 loss per share (vs ₹8.95 loss in FY 2021) Full year 2022 results: ₹5.35 loss per share (up from ₹8.95 loss in FY 2021). Revenue: ₹0 (down 100% from FY 2021). Net loss: ₹125.9m (loss narrowed 40% from FY 2021). Profit margin: (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹70.40, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 36x in the Life Sciences industry in India. Total returns to shareholders of 176% over the past three years. Reported Earnings • Feb 15
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: ₹5.90 loss per share (down from ₹5.55 loss in 3Q 2021). Revenue: ₹2.08b (up 33% from 3Q 2021). Net loss: ₹139.0m (loss widened 6.4% from 3Q 2021). Revenue missed analyst estimates by 4.7%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improved over the past week After last week's 17% share price gain to ₹84.50, the stock trades at a trailing P/E ratio of 34.6x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 160% over the past three years. Reported Earnings • Nov 12
Second quarter 2022 earnings released: EPS ₹9.51 (vs ₹1.43 loss in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹2.05b (up 35% from 2Q 2021). Net income: ₹224.0m (up ₹257.6m from 2Q 2021). Profit margin: 11% (up from net loss in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 12
First quarter 2022 earnings released: ₹6.49 loss per share (vs ₹4.19 loss in 1Q 2021) The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: ₹1.82b (up 25% from 1Q 2021). Net loss: ₹152.8m (loss widened 55% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 03
Full year 2021 earnings released: ₹8.95 loss per share (vs ₹43.97 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: ₹6.23b (down 66% from FY 2020). Net loss: ₹210.8m (loss narrowed 80% from FY 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improved over the past week After last week's 16% share price gain to ₹65.40, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 31% over the past three years. Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹50.60, the stock is trading at a trailing P/E ratio of 2.7x, down from the previous P/E ratio of 3.3x. This compares to an average P/E of 47x in the Life Sciences industry in India. Total return to shareholders over the past three years is a loss of 18%. Reported Earnings • Feb 15
Third quarter 2021 earnings released: ₹5.55 loss per share (vs ₹17.52 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹1.57b (down 53% from 3Q 2020). Net loss: ₹130.6m (down 132% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 25
New 90-day high: ₹51.25 The company is up 17% from its price of ₹43.80 on 27 October 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is up 13% over the same period. Reported Earnings • Nov 14
Second quarter 2021 earnings released: ₹1.43 loss per share The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: ₹1.56b (down 77% from 2Q 2020). Net loss: ₹33.6m (loss narrowed 98% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Sep 28
New 90-day low: ₹39.85 The company is down 31% from its price of ₹57.95 on 30 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 33% over the same period. Announcement • Aug 30
Bilcare Limited to Report Q1, 2021 Results on Sep 03, 2020 Bilcare Limited announced that they will report Q1, 2021 results on Sep 03, 2020